Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Paris – page 272

3 342 clinical trials in Paris, France across 36 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Paris at a glance
3 342
clinical trials
  • Research sites36
Type of trial
Recruitment status
Quick filters

3 342 trials in Paris

Open in trial search

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Safety and Effectiveness of Deucravacitinib for Patients with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Squamous cell carcinoma of head and neck+1

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Io Biotech ApS

Giant cell arteritis

Not recruiting

Study on Stopping Tocilizumab for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Neoplasm malignant

Not recruiting

Study on the Safety of GRWD5769 Alone and with Cemiplimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Grey Wolf Therapeutics Limited

Alopecia areata

Not recruiting

Study on Baricitinib for Treating Children Aged 6 to 17 with Alopecia Areata

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Microsatellite instability cancer+1

Not recruiting

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MK-4830
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma stage IV+1

Not recruiting

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Paris

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma and endometrial cancer, evaluating innovative treatment combinations and survival outcomes.

  • Advanced cancer therapies
  • Combination treatments
  • Survival outcome assessment
02 Metabolic Disorders

Clinical investigations targeting Type 1 Diabetes and obesity, with novel therapeutic approaches using tirzepatide for improved glycemic control.

  • Diabetes management
  • Weight control
  • Metabolic health
03 Infectious Diseases

Innovative vaccine trials for COVID-19, influenza, and cytomegalovirus, exploring both intranasal and injectable delivery methods.

  • Vaccine development
  • Immunogenicity studies
  • Prevention strategies
04 Neurological Conditions

Advanced research in multiple sclerosis and Alzheimer's disease, utilizing cutting-edge imaging techniques to study neuroinflammation and synaptic density.

  • Brain imaging
  • Neurodegenerative diseases
  • Disease progression
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.